Dermatology Covid-19, Monkeypox, and Emerging Infections Registry |
Thank you for agreeing to take part in this important effort to understand dermatologic manifestations of COVID-19, Mpox, and Drug-resistant dermatophytes. This survey is for all health care professionals taking care of a) COVID-19 or Monkeypox patients that develop dermatologic manifestations, b) dermatology patients with an existing condition that then develop COVID-19 or Monkeypox, c) dermatologic reactions to a COVID-19 or Monkeypox vaccine, or d) suspected or confirmed drug-resistant Tinea.
The case report form should take about 5-7 minutes to complete. Patient identifiers such as name or date of birth will not be collected. All de-identified information will be kept strictly confidential and will only be shared with researchers compiling information. Data will be stored on a secure Redcap server at Massachusetts General Hospital (Partners Healthcare).
The success of this collaborative effort depends on active participation by our international healthcare community to obtain accurate and reliable information. This registry is for healthcare professionals from all countries. We ask that you share this site with your colleagues and encourage them to report any cases of COVID-19, Mpox, or drug-resistant Tinea-related dermatoses. Even if you have already submitted your case to a journal, please enter a summary of the case here so we can get an accurate understanding of the range of Dermatologic manifestations from COVID-19, Mpox, or drug-resistant Tinea.
This form has been reviewed by the Massachusetts General Hospital (Partners Healthcare) institutional review board.